Compare Crispr Therapeutics AG (CRSP) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Synopsys, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.4 (market cap $4.88B), while Synopsys, Inc. trades at $508.09 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 19.5× Crispr Therapeutics AG's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Synopsys, Inc. for 71 Days on average.
| CRSP | SNPS | |
|---|---|---|
Market Cap | $4.88B | $95.39B |
Volume | 2,861,747 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $74.92 | $534.56 |
52-Week Low | $44.34 | $367.70 |
Typical Hold Time | 77 Days | 71 Days |
Enterprise Value | $3.30B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights AI-driven partnerships with OpenAI and Amazon, boosting growth prospects. Valuation ratios are elevated, with a P/E of 86.87, reflecting high growth expectations. Analyst sentiment is overwhelmingly positive, with a consensus price target of $572.54.
The outlook for SNPS is favorable, driven by AI integration and strategic acquisitions, but risks include high valuation sensitivity and competitive pressures. Revenue growth and margin expansion from new deals present opportunities, though investors should monitor execution risks and market volatility. The stock's proximity to key resistance levels suggests potential for near-term consolidation or breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
